Figure 1. Key events during the illness courses of 15 patients who received AIG-IV (10 survivors, 5 nonsurvivors) and 28 patients who did not receive AIG-IV (22 survivors, 6 nonsurvivors) from the time of their suspected exposure to contaminated heroin to the time of discharge from hospital or to death, Scotland, UK, 2009–2010. A) AIG-IV recipient who survived. B) AIG-IV recipient who died. C) AIG-IV nonrecipient who survived. D) AIG-IV nonrecipient who died. AIG-IV, anthrax immune globulin intravenous; ICU, intensive care unit; SOFA, sequential organ failure.